Metastatic Ovarian Cancer Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Metastatic Ovarian Cancer – Pipeline Review, H1 2015” to its store. The report provides data on the Metastatic Ovarian Cancer’s therapeutic pipeline.

Metastatic Ovarian Cancer Therapeutic Pipeline Review H1 2015

Metastatic Ovarian Cancer Therapeutic Pipeline Review H1 2015

Past News Releases

RSS

The report “Metastatic Ovarian Cancer - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Metastatic Ovarian Cancer. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of “Metastatic Ovarian Cancer” addiction with 25 market data tables and 13 figures, spread across 65 pages is available at http://www.rnrmarketresearch.com/metastatic-ovarian-cancer-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Metastatic Ovarian Cancer – Pipeline Review, H1 2015 report include antigen-presenting dendritic cells, DCVax-Direct, Drugs for Cancer, Drugs for Metastatic Ovarian Cancer, E-7449, G-305, hydroxychloroquine + sorafenib tosylate, IPH-2201, LV-305, orteronel, SM-276001 and Stem Cell Therapy for Oncology.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are antigen-presenting dendritic cells, DCVax-Direct, Drugs for Cancer, Drugs for Metastatic Ovarian Cancer, E-7449, G-305, hydroxychloroquine + sorafenib tosylate, IPH-2201, LV-305, orteronel, SM-276001 and Stem Cell Therapy for Oncology. Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=375212 . (This is a premium report priced at US$2000 for a single user License.)

Scope

  •     The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
  •     The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  •     The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
  •     The report summarizes all the dormant and discontinued pipeline projects
  •     A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

List of Tables

Number of Products under Development for Metastatic Ovarian Cancer, H1 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Metastatic Ovarian Cancer - Pipeline by Aura Biosciences, Inc., H1 2015 16
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2015 17
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H1 2015 18
Metastatic Ovarian Cancer - Pipeline by Innate Pharma SA, H1 2015 19
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 20
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2015 21
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Assessment by Combination Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015 50
Metastatic Ovarian Cancer - Dormant Projects, H1 2015 62
Metastatic Ovarian Cancer - Discontinued Products, H1 2015 63

List of Figures

Number of Products under Development for Metastatic Ovarian Cancer, H1 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Explore more reports on cancer therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
since: 08/2012
Like >
Follow us on
Visit website